Gall Matthew 4
4 · iTeos Therapeutics, Inc. · Filed Mar 8, 2024
Insider Transaction Report
Form 4
Gall Matthew
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2024-03-07+163,200→ 163,200 totalExercise: $11.58Exp: 2034-03-07→ Common Stock (163,200 underlying)
Footnotes (1)
- [F1]This stock option shall vest over four years, with 25% vesting on March 7, 2025 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer.